Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.

被引：0
|
作者：
Niu, Nan
Cao, Shuo
Chen, Guanglei
Xue, Jinqi
Zhang, Yu
Xu, Yongqing
Yin, Jianqiao
Liu, Chao
Jiang, Xiaofan
Tang, Meiyue
Xu, Qianshi
Jia, Mingxuan
Zhang, Xu
Zhang, Zhenyong
Li, Huajun
Li, Ailin
Liu, Caigang
机构：
[1] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
[2] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12604
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [22] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [23] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [24] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [25] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [26] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Mariya Rozenblit
    Sophia Mun
    Pamela Soulos
    Kerin Adelson
    Lajos Pusztai
    Sarah Mougalian
    Breast Cancer Research, 23
  • [27] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Pernas, Sonia
    Sanfeliu, Esther
    Villacampa, Guillermo
    Salvador, Javier
    Perello, Antonia
    Gonzalez, Xavier
    Jimenez, Begona
    Merino, Maria
    Palacios, Patricia
    Pascual, Tomas
    Alba, Emilio
    Villanueva, Lorea
    Chillara, Samyukta
    Ferrero-Cafiero, Juan Manuel
    Galvan, Patricia
    Prat, Aleix
    Ciruelos, Eva
    NPJ BREAST CANCER, 2024, 10 (01)
  • [28] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [29] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [30] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
12345